Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 106Lung Neoplasms 41Neoplasms 13Neoplasm Metastasis 11Colorectal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 6Carcinoma 6Mesothelioma, Malignant 5Mesothelioma 5Ovarian Neoplasms 4Meningeal Carcinomatosis 4Melanoma 4Colonic Neoplasms 4Advanced Solid Tumors 4Rectal Neoplasms 3Neoplasms by Site 3Lung Diseases 3Carcinoma, Bronchogenic 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Thoracic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Non-squamous Non-small Cell Lung Cancer 2Non-Small Cell Lung Cancer Metastatic 2Non Small Cell Lung Carcinoma NSCLC 2

Interventions

Carboplatin 6Radiotherapy 5Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 4Specimen Handling 3Pemetrexed 3Biopsy 3Bevacizumab 3capmatinib 2Radiotherapy, Conformal 2Platinum 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cisplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1osimertinib 1methoxyamine 1lazertinib 1fludarabine phosphate 1durvalumab 1defactinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Pemetrexed × 90 days × Clear all
NCT07624487 2026-06-03

A Phase II Study of Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

Taipei Medical University Hospital

Phase 2 Not yet recruiting
50 enrolled
Thoracic

Adenocarcinoma of Lung

NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT05456256 2026-05-04

HARMONIC

Lantern Pharma Inc.

Phase 2 Recruiting
90 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡